ClinicalTrials.gg
RecruitingNCT06148025AVIRSUpdated Sep 17, 2026

Antibiotics and Vaccine Immune Responses Study

A Phase 4 interventional study of BCG vaccine and Yellow Fever vaccine in Vaccine Response Impaired, sponsored by South Australian Health and Medical Research Institute. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by South Australian Health and Medical Research Institute · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.

The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Read the detailed description

The study is divided into two sub-studies. The first sub-study (BCG re-challenge) is an experimental medicine study in 168 healthy participants to determine if depletion of the gut microbiota leads to impaired BCG-induced protection against a subsequent Mycobacterium bovis BCG intradermal challenge.

The second sub-study (Yellow Fever vaccine) has a very similar experimental design to the first but will determine if depletion of the gut microbiota leads to impaired BCG-induced protection against other infections. To assess this, participants in this sub-study (n=180) will be re-challenged after 3 months with a live attenuated viral vaccine, the Yellow Fever vaccine, which induces a mild viremia.

In both sub-studies, participants will initially be randomised to receive a 3 day course of antibiotics or none (comparator group). The two groups in each sub-study will be randomised again to receive either BCG vaccine or 0.9% NaCl placebo injection in the left arm.

BCG re-challenge sub-study (Sub-study 1): Six months following randomisation, all participants will receive a BCG vaccine challenge in the right arm. A punch skin biopsy will be taken of this challenge site 2 weeks after the challenge to assess M. bovis BCG bacterial load in the skin.

Yellow Fever vaccine sub-study (Sub-study 2): Three months following randomisation, all participants will receive a Yellow Fever vaccine challenge in the right arm. Blood samples will be collected from Yellow Fever vaccinated participants at day 3, 5 and 7 following Yellow Fever vaccine challenge to quantify Yellow Fever viral load in blood.

All participants in both sub-studies will have blood samples collected at randomisation, before each vaccination, 2 weeks after each BCG vaccination and in the Yellow Fever vaccine sub-study at day 3, 5 and 7 following Yellow Fever vaccination. Stool samples will be collected prior to randomisation, and prior to each vaccination.

02

Conditions studied

  • Vaccine Response Impaired

Keywords

  • Healthy participants
  • 18-35 years old
  • BCG vaccine
  • Yellow Fever vaccine
  • Antibiotics
03

In context

Lead sponsor

South Australian Health and Medical Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-35 years old
  • Provided a signed and dated form
  • BCG naïve (Arm 1) and BCG and YF vaccine naïve (Arm 2)
  • Willing to take short antibiotic course
  • Willing to undergo a punch (Arm 1)
  • Willing to have up to 7 blood samples and 3 stool samples collected over 5-7 months
  • Not pregnant or intending to get pregnant for the duration of the study (a pregnancy test will be offered to females)

Exclusion criteria

Exclusion Criteria:

  • Previous BCG vaccination
  • Previous YF vaccination or YFV infection (only applies to participants included in the Yellow Fever Vaccine challenge sub-study)
  • Evidence of TB infection (assessed through a questionnaire - IGRA to confirm if needed)
  • People with for BCG vaccination:

    • involving bone marrow or lymphoid systems, primary or secondary immunodeficiencies, infection
    • moderate/severe skin disease including eczema, dermatitis or psoriasis
    • requiring drugs or other immune modifying drugs e.g. , non-biological immunosuppressants, biological agents (such as monoclonal antibodies against tumour necrosis factor (TNF)-alpha)
  • People with contraindications to YF vaccination:

    • History of thymus disease, including myasthenia gravis, thymoma, thymectomy, DiGeorge syndrome, thymic damage from chemoradiotherapy or
    • YF vaccination is contraindicated in immunocompromised individuals, including individuals who have HIV infection, primary immunodeficiencies (including inherited IFNAR1 deficiency), or are taking corticosteroids or other immunosuppressive agents and haematopoietic stem cell transplant recipients
    • People who have had a haematopoietic stem cell transplant
    • Individuals with history of severe allergic reactions to egg or chicken proteins
  • Pregnant or breastfeeding or planning to become pregnant
  • History of renal disease/insufficiency
  • Tattoo obscuring BCG vaccination site(s)
  • Any history of severe allergic reaction or anaphylaxis to vaccination or antibiotics
  • People with chronic serious underlying illness
  • Have received any prescribed oral or intravenous antibiotic in the 28 days prior to study visits 1 and 4 (including isoniazid, rifampicin, streptomycin and ethambutol as these particular antibiotics have activity against M. bovis)
  • Have received any vaccinations in the 28 days prior to study visits 1 and 4
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
348 participants (estimated)

Study arms

  • Experimental
    Substudy 1 - BCG vaccine, antibiotics and 2nd BCG vaccine

    Randomised to receive antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later

    Biological: BCG vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl

  • Experimental
    Substudy 1 - BCG vaccine, no antibiotics and 2nd BCG vaccine

    Randomised to receive no antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later

    Biological: BCG vaccine

  • Experimental
    Substudy 1 - BCG vaccine, antibiotics and placebo vaccine

    Randomised to receive antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later

    Biological: BCG vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl

  • Experimental
    Substudy 1 - BCG vaccine, no antibiotics and placebo vaccine

    Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later

    Biological: BCG vaccine

  • Experimental
    Substudy 2 - Yellow Fever vaccine, antibiotics and BCG vaccine

    Randomised to receive antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later

    Biological: BCG vaccine · Biological: Yellow Fever vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl

  • Experimental
    Substudy 2 - Yellow Fever vaccine, no antibiotics and BCG vaccine

    Randomised to receive no antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later

    Biological: BCG vaccine · Biological: Yellow Fever vaccine

  • Experimental
    Substudy 2 - Yellow Fever vaccine, antibiotics and placebo vaccine

    Randomised to receive antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later

    Biological: Yellow Fever vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl

  • Experimental
    Substudy 2 - Yellow Fever vaccine, no antibiotics and placebo vaccine

    Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later

    Biological: Yellow Fever vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Sub-study 1 BCG re-challenge

    Mycobacterial load (Colony Forming Units (CFU)/mg tissue) in the skin biopsy site in BCG-vaccinated participants not exposed to antibiotics (BCG-No ABX) compared to BCG-vaccinated participants that were exposed to antibiotics (BCG-ABX)

    Time frame: 2 weeks post BCG challenge

  2. Sub-study 2 Yellow Fever vaccine

    Peak Yellow Fever viremia (viral copies/ml plasma) at day 3-7 post YFV vaccination in BCG-vaccinated participants not exposed to antibiotics (BCG-No ABX) compared to BCG-vaccinated participants that were exposed to antibiotics (BCG-ABX)

    Time frame: 3, 5, 7 days post YFV challenge

Secondary outcomes

  1. Sub-study 1 - Bacterial load

    Bacterial load (16S rRNA gene copies/g stool) in ABX participants compared to No-ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of BCG challenge

  2. Sub-study 2 - Bacterial load

    Bacterial load (16S rRNA gene copies/g stool) in ABX participants compared to No-ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of YFV challenge

  3. Sub-study 1 - Microbiota diversity

    Microbiota diversity (Shannon diversity index) in ABX participants compared to No-ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of BCG challenge

  4. Sub-study 2 - Microbiota diversity

    Microbiota diversity (Shannon diversity index) in ABX participants compared to No-ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of YFV challenge

  5. Sub-study 1 - Mycobacterial load

    Mycobacterial load (CFU/mg tissue) in the skin biopsy site of BCG-vaccinated participants compared to placebo-vaccinated participants

    Time frame: 2 weeks post BCG challenge

  6. Sub-study 1 - Mycobacterial-specific IFNγ responses

    Mycobacterial-specific IFNγ responses (number of spot-forming units) in BCG-ABX participants compared to BCG-No ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), 2 weeks post vaccination, Day of BCG challenge and 2 weeks post BCG challenge

  7. Sub-study 1 - Mycobacterial-specific CD4+ T cell activation marker responses

    Mycobacterial-specific T cell activation-induced marker expression (frequency of OX40+CD137+ CD4+ T cells) in BCG-ABX participants compared to BCG-No ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), 2 weeks post vaccination, Day of BCG challenge and 2 weeks post BCG challenge

  8. Sub-study 1 - Mycobacterial-specific CD8+ T cell activation marker responses

    Mycobacterial-specific T cell activation-induced marker expression (frequency of CD69+CD137+ cells of CD8+ T cells) in BCG-ABX participants compared to BCG-No ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), 2 weeks post vaccination, Day of BCG challenge and 2 weeks post BCG challenge

  9. Sub-study 2 - Peak viraemia

    Peak viraemia (viral copies/ml plasma) at day 3-7 post YFV challenge in BCG-vaccinated participants compared to placebo-vaccinated participants

    Time frame: 3, 5 and 7 days post YFV challenge

  10. Sub-study 2 - Heterologous TNFα responses following R848 stimulation

    TNFα cytokine production (pg/mL) following stimulation of PBMC with resiquimod (R848) in BCG-ABX participants compared to BCG-No ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination) and Day of YFV challenge

  11. Sub-study 2 - Heterologous TNFα responses following LPS stimulation

    TNFα cytokine production (pg/mL) following stimulation of PBMC with lipopolysaccharide (LPS) in BCG-ABX participants compared to BCG-No ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination) and Day of YFV challenge

  12. Sub-study 2 - Heterologous TNFα responses following HKCA stimulation

    TNFα cytokine production (pg/mL) following stimulation of PBMC with heat-killed Candida albicans (HKCA) in BCG-ABX participants compared to BCG-No ABX participants

    Time frame: Baseline (1-2 weeks before BCG/placebo vaccination) and Day of YFV challenge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Non-identifiable individual participant data from the study may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept SAHMRI's conditions, under a collaborator agreement, for accessing: Individual participant data that underlie the results reported in our articles after deidentification (text, tables, figures and appendices) Study protocol, Statistical Analysis Plan, PICF Molecular data generated from this study (i.e. transcriptomic, epigenomic and metagenomic) will be labelled with a unique identification code and stored on an appropriate data repository (e.g. Gene Expression Omnibus, Sequence Read Archive) with demographic information (age and sex). No identifying participant information will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: At time of publication. Data will be available indefinitely.

Access criteria: Researchers from a recognised research institution can approach SAHMRI for access of data. The researcher will need to provide evidence that the proposed use of the data has been ethically reviewed and approved by an Institutional Review Board (IRB)/ Human Research Ethics Committee(HREC), and accept SAHMRI's conditions, under a collaborator agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Oct 2027, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Nov 28, 2023
StartActual
Nov 23, 2023
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06148025
Lead sponsor
South Australian Health and Medical Research Institute
Collaborators
Royal Adelaide Hospital, Flinders University, University of Sydney, Telethon Kids Institute, Centenary Institute
Responsible party
David Lynn (Director, Computational & Systems Biology Program, South Australian Health and Medical Research Institute) — Principal investigator
First posted
Nov 28, 2023
Start date
Nov 23, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

David Lynn
Contact
david.lynn@sahmri.com
+61 8 8128 4053
David Lynn
principal investigator · South Australian Health and Medical Research Institute
Simone Barry
principal investigator · Royal Adelaide Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BCG Vaccine · Yellow Fever Vaccine · Vancomycin · Neomycin · Metoclopramide · Loperamide

Start the discussion